Details of the Drug Reposition

General Information of This Drug (ID: DMHJ1Y0)

Drug Name
NKX101   DMHJ1Y0
Drug Type
CAR T Cell Therapy

Information on Drug Reposition of This Drug

Molecular Interaction Atlas (MIA)
2 Phase 1 Indication(s)
Indication Name Indication ID ICD-11 Status REF
Myelodysplastic syndrome DISYHNUI 2A37 Phase 1 [1]
Acute myeloid leukaemia DIS0BM1I 2A60 Phase 1 [1]
------------------------------------------------------------------------------------

References

1 ClinicalTrials.gov (NCT04623944) NKX101, Intravenous Allogeneic Engineered Natural Killer Cells, in Adults With AML or MDS. U.S. National Institutes of Health.